Last 7 days
-1.4%
Last 30 days
-5.3%
Last 90 days
-46.3%
Trailing 12 Months
-85.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 126.4B | 26.3B | 1.33% | 2.31% | 19.3 | 4.8 | 1.32% | 11.18% |
GILD | 99.2B | 27.3B | -0.40% | 40.80% | 21.61 | 3.64 | -0.09% | -26.23% |
MRNA | 57.1B | 19.3B | 6.53% | -10.59% | 6.83 | 2.96 | 4.29% | -31.47% |
BIIB | 39.0B | 10.2B | -0.01% | 27.97% | 12.8 | 3.83 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.4B | 1.5B | -5.27% | 3.55% | 60.62 | 6.29 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -10.19% | -29.91% | -9.71 | 29.17 | 122.90% | -12.19% |
BEAM | 2.2B | 60.9M | -21.53% | -47.37% | -7.53 | 35.73 | 17.51% | 22.00% |
BBIO | 2.2B | 107.9M | 22.92% | 38.22% | -4.45 | 19.98 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 112.0M | -3.60% | -50.92% | -4.82 | 11.49 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -2.83% | 20.33% | -6.95 | 155.42 | 131.81% | -45.39% |
FATE | 533.2M | 96.3M | -5.35% | -85.58% | -1.89 | 5.54 | 72.44% | -32.79% |
NVAX | 524.0M | 2.0B | -30.95% | -91.78% | -0.8 | 0.26 | 72.89% | 62.27% |
SGMO | 290.2M | 111.3M | -34.46% | -69.74% | -1.51 | 2.61 | 0.54% | -7.86% |
VXRT | 102.0M | 107.0K | -5.82% | -84.77% | -0.95 | 953.19 | -88.00% | -52.91% |
IBIO | 30.1M | - | 102.50% | -80.56% | -0.37 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 39.5% | 96,300,000 | 69,013,000 | 68,257,000 | 63,120,000 | 55,846,000 |
Operating Expenses | 5.8% | 404,686,000 | 382,362,000 | 349,838,000 | 308,371,000 | 272,840,000 |
S&GA Expenses | 5.8% | 84,232,000 | 79,584,000 | 73,747,000 | 65,564,000 | 57,321,000 |
R&D Expenses | 5.8% | 320,454,000 | 302,778,000 | 276,091,000 | 242,807,000 | 215,519,000 |
Interest Expenses | - | 0.00 | - | - | - | - |
Net Income | 4.2% | -281,721,000 | -293,979,000 | -253,724,000 | -232,752,000 | -212,151,000 |
Net Income Margin | 31.3% | -2.93 | -4.26 | -3.72 | -3.69 | - |
Free Cahsflow | 2.3% | -283,774,000 | -290,370,000 | -274,757,000 | -257,194,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -5.8% | 706 | 749 | 807 | 858 | 921 |
Current Assets | -6.2% | 502 | 535 | 599 | 599 | 633 |
Cash Equivalents | -25.3% | 61.00 | 82.00 | 55.00 | 65.00 | 134 |
Net PPE | 0.8% | 110 | 109 | 103 | 98.00 | 92.00 |
Current Liabilities | 9.7% | 114 | 104 | 92.00 | 78.00 | 81.00 |
Shareholder's Equity | -6.6% | 484 | 518 | 580 | 633 | 679 |
Retained Earnings | -5.7% | -1,050 | -994 | -910 | -834 | -769 |
Additional Paid-In Capital | 1.4% | 1,536 | 1,516 | 1,495 | 1,471 | 1,449 |
Shares Outstanding | 0.2% | 97.00 | 97.00 | 97.00 | 97.00 | 96.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -2.1% | -248 | -243 | -221 | -200 | -162 |
Share Based Compensation | 6.5% | 79.00 | 74.00 | 68.00 | 61.00 | 54.00 |
Cashflow From Investing | -9.8% | 167 | 185 | 182 | 141 | -324 |
Cashflow From Financing | -17.1% | 9.00 | 11.00 | 18.00 | 18.00 | 453 |
100%
98.1%
32.7%
Y-axis is the maximum loss one would have experienced if Fate Therapeutics was unfortunately bought at previous high price.
16.8%
-10.5%
-37.2%
FIve years rolling returns for Fate Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | unchanged | - | -542,130 | 444,000 | -% |
2023-03-17 | American Portfolios Advisors | added | 15.03 | 2,590 | 66,894 | -% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | -4,247 | 3,753 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -22.54 | -14,316,600 | 7,666,400 | 0.01% |
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | - | - | -% |
2023-03-03 | TIAA, FSB | unchanged | - | -216,497 | 177,503 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -393,513 | 322,487 | -% |
2023-02-24 | NATIXIS | new | - | 28,968 | 28,968 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -40,000 | - | -% |
2023-02-17 | Coppell Advisory Solutions Corp. | new | - | 42,277 | 42,277 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 22, 2023 | millennium management llc | 1.7% | 1,696,431 | SC 13G | |
Mar 10, 2023 | vanguard group inc | 10.12% | 9,936,042 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 5.8% | 5,591,517 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 8.20% | 7,972,551 | SC 13G/A | |
Feb 03, 2023 | state street corp | 6.11% | 5,935,459 | SC 13G | |
Jan 06, 2023 | blackrock inc. | 10.0% | 9,725,895 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 10.80% | 10,312,167 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 7.4% | 7,060,552 | SC 13G/A | |
Oct 12, 2021 | fmr llc | - | 0 | SC 13G/A | |
Sep 10, 2021 | ark investment management llc | 11.34% | 10,790,423 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.22 -95.99% | 0.47 -91.42% | 1.42 -74.09% | 3.03 -44.71% | 6.27 14.42% |
Current Inflation | 0.20 -96.35% | 0.42 -92.34% | 1.25 -77.19% | 2.64 -51.82% | 5.39 -1.64% |
Very High Inflation | 0.17 -96.90% | 0.37 -93.25% | 1.05 -80.84% | 2.17 -60.40% | 4.39 -19.89% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 22, 2023 | SC 13G | Major Ownership Report | |
Mar 10, 2023 | SC 13G/A | Major Ownership Report | |
Feb 28, 2023 | 10-K | Annual Report | |
Feb 28, 2023 | 8-K | Current Report | |
Feb 13, 2023 | SC 13G | Major Ownership Report | |
Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
Feb 07, 2023 | 4 | Insider Trading | |
Feb 07, 2023 | 4 | Insider Trading | |
Feb 07, 2023 | 4 | Insider Trading | |
Feb 07, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-01-19 | MENDLEIN JOHN | acquired | 38,991 | 1.37 | 28,461 | - |
2023-01-13 | MENDLEIN JOHN | bought | 198,906 | 5.43 | 36,631 | - |
2023-01-12 | Valamehr Bahram | acquired | 579 | 1.37 | 423 | chief r&d officer |
2023-01-11 | MENDLEIN JOHN | bought | 499,232 | 5.67 | 88,048 | - |
2023-01-10 | TAHL CINDY | sold | -60,537 | 5.24 | -11,553 | general counsel and secretary |
2023-01-10 | Wolchko J Scott | sold | -240,553 | 5.24 | -45,907 | president and ceo |
2023-01-10 | Plavsic Mark | sold | -17,910 | 5.24 | -3,418 | chief technical officer |
2023-01-10 | Dulac Edward J III | sold | -38,414 | 5.24 | -7,331 | chief financial officer |
2023-01-10 | Chu Yu-Waye | sold | -41,003 | 5.24 | -7,825 | chief medical officer |
2023-01-10 | Valamehr Bahram | sold | -57,205 | 5.24 | -10,917 | chief r&d officer |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Collaboration revenue | $ 96,300 | $ 55,846 | $ 31,434 |
Type of Revenue [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember | us-gaap:LicenseMember |
Operating expenses: | |||
Research and development | $ 320,454 | $ 215,519 | $ 125,623 |
General and administrative | 84,232 | 57,321 | 33,896 |
Total operating expenses | 404,686 | 272,840 | 159,519 |
Loss from operations | (308,386) | (216,994) | (128,085) |
Other income (expense): | |||
Interest income | 5,842 | 1,309 | 2,400 |
Change in fair value of stock price appreciation milestones | 20,307 | 3,534 | (47,702) |
Other income | 516 | 0 | 0 |
Total other income (expense), net | 26,665 | 4,843 | (45,302) |
Net loss | (281,721) | (212,151) | (173,387) |
Other comprehensive loss: | |||
Unrealized (loss) gain on available-for-sale securities, net | (1,092) | (832) | 48 |
Comprehensive loss | $ (282,813) | $ (212,983) | $ (173,339) |
Earnings Per Share, Basic | $ (2.91) | $ (2.24) | $ (2.10) |
Earnings Per Share Diluted | $ (2.91) | $ (2.24) | $ (2.10) |
Weighted Average Number of Shares Outstanding, Basic | 96,826,058 | 94,747,311 | 82,385,319 |
Weighted Average Number of Shares Outstanding, Diluted | 96,826,058 | 94,747,311 | 82,385,319 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 61,333 | $ 133,583 |
Accounts receivable | 38,480 | 8,676 |
Short-term investments | 374,894 | 482,327 |
Prepaid expenses and other current assets | 27,367 | 8,826 |
Total current assets | 502,074 | 633,412 |
Long-term investments | 4,942 | 100,664 |
Property and equipment, net | 110,020 | 91,529 |
Operating lease right-of-use assets | 66,069 | 70,720 |
Restricted cash | 15,227 | 15,227 |
Collaboration contract assets | 7,196 | 9,870 |
Other assets | 33 | 33 |
Total assets | 705,561 | 921,455 |
Current liabilities: | ||
Accounts payable | 8,265 | 8,612 |
Accrued expenses | 53,932 | 42,412 |
CIRM award liability, current portion | 4,000 | 3,200 |
Deferred revenue, current portion | 42,226 | 21,483 |
Operating lease liabilities, current portion | 5,628 | 5,577 |
Total current liabilities | 114,051 | 81,284 |
Deferred revenue, net of current portion | 0 | 27,124 |
CIRM award liability, net of current portion | 0 | 800 |
Operating lease liabilities, net of current portion | 103,710 | 109,241 |
Stock price appreciation milestones, net of current portion | 3,861 | 24,168 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; authorized shares--5,000,000 at December 31, 2022 and December 31, 2021; Class A Convertible Preferred shares issued and outstanding--2,794,549 at December 31, 2022 and December 31, 2021 | 3 | 3 |
Common stock, $0.001 par value; authorized shares--250,000,000 at December 31, 2022 and December 31, 2021; issued and outstanding --97,294,917 at December 31, 2022 and 95,726,962 at December 31, 2021 | 97 | 96 |
Additional paid-in capital | 1,536,497 | 1,448,584 |
Accumulated other comprehensive (loss) gain | (1,854) | (762) |
Accumulated deficit | (1,050,804) | (769,083) |
Total stockholders’ equity | 483,939 | 678,838 |
Total liabilities and stockholders’ equity | $ 705,561 | $ 921,455 |